Want to see APYX full AI Analyst Report?
APYX Stock Chart & Stats
$3.05
-$0.03(-0.77%)
At close: 4:00 PM EDT
$3.05
-$0.03(-0.77%)
Day’s Range― - ―
52-Week Range$1.70 - $5.08
Previous Close$3.83
Volume71.39K
Average Volume (3M)129.90K
Market Cap
$129.74M
Enterprise Value$209.33
Total Cash (Recent Filing)$27.62M
Total Debt (Recent Filing)$39.63M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding42,124,023
10 Day Avg. Volume153,056
30 Day Avg. Volume129,897
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside113.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$59.55M
Bulls Say, Bears Say
Bulls Say
Surgical Aesthetics GrowthStrong growth in the core Surgical Aesthetics segment, supported by AYON, international Renuvion systems and domestic handpieces, can expand the installed base and recurring consumable revenue over the next several years.
Product And Regulatory ExpansionPower Lipo broadens AYON’s clinical utility and increases the potential value of each system placement. Management expects more than 95% of new AYON purchasers to include it, supporting adoption and future consumables demand.
Clinical Platform ValidationPositive clinical evidence can strengthen surgeon confidence, patient demand and regulatory positioning for Renuvion-based procedures. Broader validation may support durable adoption across aesthetic indications and reinforce the company’s technology platform.
Bears Say
Persistent Cash BurnNegative operating and free cash flow show that the business has not yet funded itself internally. Continued investment in commercialization and product launches may require external funding, limiting flexibility and increasing execution risk.
Elevated LeverageDebt materially exceeds the equity base, leaving a thin cushion against operating setbacks. Combined with ongoing losses, this leverage can constrain investment capacity, increase refinancing exposure and heighten dilution or funding risk.
Profitability And OEM PressureThe company remains loss-making while the declining OEM segment reduces revenue diversification. Early Power Lipo units also carry higher production costs, so margin recovery depends on manufacturing scale, cost control and successful growth in aesthetics.
Apyx Medical News
APYX FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was $1.70 and its highest was $5.08 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is $129.74M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.012.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.1.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 42,124,023 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -2.644%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in APYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (113.11% Upside)
$6.50 (113.11% Upside)
Blogger Sentiment
Bearish
APYX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 662.8K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
APYX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.View all APYX earnings summariesAPYX Stock 12 Month Forecast
Average Price Target
$6.50
▲(113.11% Upside)
Technical Analysis
Ownership Overview
6.77% Insiders
8.83% Mutual Funds
35.45% Other Institutional Investors
44.96% Public Companies and
Individual Investors